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Abstract 
Background: Recurrent urinary tract infections are a significant problem in women and the current 
mainstay of prophylactic therapy is long-term antibiotic use. Based on recent studies, there is a possible 
natural remedy that could reduce the use of antibiotics for preventative medicine in recurrent urinary tract 
infections. This would decrease the chance of antibiotic resistance and the side effects of the antibiotics 
to the user. 
Methods: An exhaustive search of CINAHL, MEDLINE-Ovid, MEDLINE-PubMed, and Web of Science with 
the search terms “D-mannose” and “recurrent urinary tract infection” was performed. Eligible articles were 
assessed using the GRADE criteria. 
Results: The search provided two pertinent articles comparing the efficacy of D-mannose to antibiotic 
therapy. Kranjcec et al4 demonstrated that there was no significant difference between nitrofurantoin and 
D-mannose therapy, but the side-effects of the antibiotic were considerable. Porru et al5 displayed a 
significant decrease in recurrence of urinary tract infections in the D-mannose group compared to the 
trimethoprim/sulfamethoxazole group. 
Conclusion: D-mannose may become a useful prophylactic therapy for recurrent urinary tract infections, 
but further studies need to be performed to determine the efficacious dose and frequency of the therapy. 
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Abstract   
Background: Recurrent urinary tract infections are a significant 
problem in women and the current mainstay of prophylactic therapy is 
long-term antibiotic use. Based on recent studies, there is a possible 
natural remedy that could reduce the use of antibiotics for 
preventative medicine in recurrent urinary tract infections. This would 
decrease the chance of antibiotic resistance and the side effects of the 
antibiotics to the user.  
 
Methods:  An exhaustive search of  CINAHL, MEDLINE-Ovid, 
MEDLINE-PubMed, and Web of Science with the search terms “D-
mannose” and “recurrent urinary tract infection” was performed. 
Eligible articles were assessed using the GRADE criteria.  
 
Results: The search provided two pertinent articles comparing the 
efficacy of D-mannose to antibiotic therapy. Kranjcec et al4 
demonstrated that there was no significant difference between 
nitrofurantoin and D-mannose therapy, but the side-effects of the 
antibiotic were considerable. Porru et al5 displayed a significant 
decrease in recurrence of urinary tract infections in the D-mannose 
group compared to the trimethoprim/sulfamethoxazole group.  
 
Conclusion: D-mannose may become a useful prophylactic therapy 
for recurrent urinary tract infections, but further studies need to be 
performed to determine the efficacious dose and frequency of the 
therapy.  
 
Keywords: D-mannose and recurrent urinary tract infections   
 - 4 - Revised 26Jul2016 
 
Acknowledgements 
 
 To my family: Thank you for believing in me even when I 
didn’t. You have been a consistent support that has truly gotten 
me to where I am today.  
 
 To my partner, Ryan: Thank you for all the love and 
support that you have shown through these last two years. You 
have put in just as much work, if not more, than I have and you 
deserve so much more recognition than this paragraph can offer.   
 
 - 5 - Revised 26Jul2016 
Table of Contents 
 
Biography .................................................................................. 2 
Abstract..................................................................................... 3 
Acknowledgements...................................................................... 4 
Table of Contents........................................................................ 5 
List of Tables .............................................................................. 6 
List of Appendices ............................Error! Bookmark not defined. 
BACKGROUND ............................................................................ 7 
METHODS .................................................................................. 8 
RESULTS ................................................................................... 9 
DISCUSSION............................................................................ 12 
CONCLUSION ........................................................................... 15 
References ............................................................................... 16 
Table I. Characteristics of Reviewed Studies ................................. 17 
Table II. Summary of Findings .................................................... 18 
 
 - 6 - Revised 26Jul2016 
 
List of Tables  
 
Table 1:     Quality Assessment of Reviewed Studies  
Table 2:     Summary of Finding  
 
 
 
 
 
List of Abbreviations 
 
CDAD Clostridium Difficile Associated Disease 
UTI  Urinary Tract Infection 
CFU  Colony Forming Units 
LUTS  Lower Urinary Tract Symptoms 
GRADE Grading of Recommendations, Assessment, Development, 
and Evaluation 
 
 
 - 7 - Revised 26Jul2016 
The Efficacy of D-mannose in the Prevention of 
Recurrent Urinary Tract Infections Compared to 
Long-Term Antibiotic Therapy.  
 
BACKGROUND 
 Urinary tract infections (UTI) are a frequent chief complaint for primary care 
visits. It is estimated that in 2007, 8.6 million people were treated for a UTI in medical 
centers across the United States, 60% of those being primary care settings.1 In 2010, they 
estimated that the annual cost for treatment of urinary tract infections is approximately 
$2.3 billion in the United States.2 Of those that suffer from a urinary tract infection, many 
experience a recurrence. In a national study3 completed in 2016, 102 out of 100 000 
females were found to suffer from recurrent urinary tract infections. This is defined as 
greater than 1 UTI in a 6-month period or 3 or more in a 12-month period.3-5 This 
translates into a greater number of primary care visits and higher prescription costs.  
The current mainstay of treatment for this complaint is to prescribe long-term 
antibiotic therapy for prophylactic measures. The most commonly used are 
nitrofurantoin, trimethoprim/sulfamethoxazole (TMP/SMX), or ciprofloxacin.6 There are 
many negative outcomes with this treatment strategy such as Clostridium difficile 
associated disease (CDAD), decreased efficacy of birth control, and antibiotic resistance.7  
Currently, the most commonly prescribed and safest antibiotic for prevention of recurrent 
urinary tract infections is Nitrofurantoin, which can cause acute pulmonary 
hypersensitivity or pneumonitis, liver damage, and blood dyscrasias.8,9 In 1980, a study9 
in Sweden reported that Nitrofurantoin represented 10-12% of reports of adverse 
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reactions to medications with 48% of those being pulmonary reactions. An alternative 
therapy needs to be discovered due to the negative effects of antibiotics and the extensive 
medical and prescription costs.  
This conclusion led to the study of a hypothesized treatment method: cranberry 
juice. This natural remedy has been studied for many years as a treatment or preventative 
method for urinary tract infections. The fruit is suspected to have properties that reduced 
bacterial adherence. However, studies did not form a consensus based on irregular results 
and the inability to determine effective formulation and dose. This led to the study of D-
mannose, the sugar found in cranberries, as well as, other fruits.5 Bacteria have 
projections called pili that adhere to the wall of the urinary tract causing the infection. 
The sugar is thought to bind to the pili of the bacteria inhibiting it from adhering to the 
epithelial cells of the urinary tract.4 This allows the bacteria to be voided through the 
urine attached to excess D-mannose. However, before providers begin to recommend this 
therapy in place of the current standard antibiotic prophylaxis, the efficacy of D-mannose 
in the prevention of recurrent urinary tract infections in women compared to long-term 
antibiotic therapy needs to be determined. 
METHODS 
 A comprehensive search of CINAHL, MEDLINE-Ovid, MEDLINE-PubMed, and 
Web of Science with the search terms “D-mannose” and “recurrent urinary tract 
infection” was performed. Due to the lack of relevant articles, an additional search was 
conducted using Google and the search terms “D-mannose” and “recurrent urinary tract 
infection.”  
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The articles were chosen based on the eligibility criteria. This included defining 
recurrent urinary tract infections (UTIs) as 2 or more positive urine cultures in 6 months 
or 3 or more in 12 months, comparing D-mannose therapy to antibiotic therapy, and 
determining recurrences of UTIs during administration of the therapies. Other inclusion 
criteria included human studies and those published in English. Applicable articles were 
assessed for quality using the Grading of Recommendations, Assessment, Development, 
and Evaluation (GRADE). 
RESULTS 
The search of the prominent databases produced 180 results. Out of these, 3 were 
repeats and 14 were deemed relevant. Three of the pertinent articles were in German and 
only 1 out of the 14 answered the clinical question. The Google search produced a 
relevant article from the Journal of Clinical Urology that was not found on any of the 
databases. Both chosen articles4,5 were randomized control trials, with the second being a 
cross-over study. See Tables 1 and 2. 
Kranjcec et al 
 This study4 was a randomized control trial that compared a D-mannose therapy 
group, a nitrofurantoin therapy group, and a non-prophylaxis group. The authors wanted 
to look at both the rate and frequency of recurrence of UTIs, as well as the complications 
of the various therapies.4 
 All patients enrolled in the study were over 18, suffered from recurrent UTIs, and 
were currently diagnosed with acute cystitis. The diagnostic criteria included a clean void 
of 1 mL midstream urine with 103 or more colony forming units (CFU) along with at least 
2 lower urinary tract infection symptoms (LUTS). These consisted of dysuria, frequency, 
urgency, suprapubic pain, nocturia, and hematuria. Patients were excluded from the study 
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if they were pregnant, trying to conceive, or breastfeeding; had symptoms of an upper 
urinary tract infection, systemic inflammatory involvement (fever or elevated white blood 
cell count), urinary tract anomalies, interstitial cystitis, or diabetes; were taking hormone 
therapy or contraception; or had already received antibiotics for their current acute 
cystitis. The 308 participants that met eligibility criteria were treated with ciprofloxacin 
500 mg twice daily for 1 week and then identified as treated once their urine displayed 
less than 103 CFU and did not report any LUTS. They were then randomized into the 3 
groups by throwing the dice.4  
 The first group was identified as the D-mannose group and received 2 grams of 
D-mannose powder diluted in 2 mL of water once daily in the evening, the second group 
received 50 mg of nitrofurantoin once daily in the evening, and group 3 received no 
prophylaxis. During the 6 months of the study, if a patient reported symptoms of a UTI, a 
clean urine sample was taken and the number of CFUs were identified. If the participant 
displayed greater than 103 CFU they were diagnosed with a UTI and were removed from 
the study to be treated with antibiotics.4 
 At the completion of the trial, there were 15 reported UTIs out of the 103 
participants in the D-mannose group, 21 out of the 103 in the nitrofurantoin group and 62 
out of the 102 in the no prophylaxis group. The study4 reported the difference in 
recurrence of the D-mannose and nitrofurantoin group as not significant. See Table 2. 
However, the reported side-effects were significantly lower in those taking D-mannose 
compared to those taking nitrofurantoin. Only 8 (8%) in the D-mannose group reported 
complications, all of which were diarrhea, where 29 (28%) in the nitrofurantoin group 
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reported various side-effects including diarrhea, nausea, headache, skin rash, and vaginal 
burning (RR of 3.5 and NNH of 5).4  
Porru et al 
 This study5 was identified as a randomized control study with cross-over that was 
comparing the rate and frequency of UTI recurrence in a therapy group treated with D-
mannose and one treated with trimethoprim/sulfamethoxazole (TMP/SMX).5  
 Eligibility criteria included females over 18 who currently have documented acute 
cystitis with greater than 105 CFUs and have had more than 3 UTIs in the past 12 months. 
Patients were excluded if they were pregnant or attempting to conceive; had an upper 
UTI, and/or temperature >38° C, flank/lumbar pain or tenderness, renal disease, 
anatomical abnormalities, prior gynecological surgery, or immunosuppressive 
medications or disease; or had taken antimicrobials in the last 4 weeks.5  
 There were 60 eligible participants that were randomly placed into 2 groups; a D-
mannose group and a TMP/SMX group. The D-mannose group was instructed to take 1 g 
of oral D-mannose three times a day, separated by 8 hours, for 2 weeks, then the dose 
decreased to 1 g twice daily for 22 weeks. The TMP/SMX group had a regimen of 160 
mg/800 mg tablets twice a day for 5 days, and subsequently 1 dose at bedtime for 1 week 
each month. The study wanted to maintain efficacy of the D-mannose which works the 
best at a neutral pH; therefore, the patients were instructed to measure urinary pH with 
dipsticks and adjust as necessary with sodium bicarbonate or potassium citrate if pH was 
<7. After 24 weeks of the study, the participants switched groups and followed the other 
groups regimen in order to obtain a larger sample size.5 
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 The study’s primary outcome measurement was the time to recurrence of UTI in 
the 2 groups, and the secondary outcome was the visual analogue scale for pain and 
urgency (VAS). If a participant complained of UTI symptoms both a urine culture and 
VAS were taken. If the culture displayed greater than 100 000 CFU, the urine was 
considered positive.5 
 Only 12 out of the 60 (20%) cross-over participants in the D-mannose group had a 
positive urine culture following the 24 weeks of the study and 45 out of the 60 (75%) 
participants that took TMP/SMX had one recurrence, 10/60 (17%) had two, leaving 5/60 
(8%) who did not have a recurrence. The mean time to recurrence for the D-mannose 
group was 200 days, while it was 52.7 days for the antibiotic group. This study displayed 
a significant difference between the D-mannose group and the antibiotic group.5 
DISCUSSION 
 Due to the data in these studies,4,5 there is significant evidence to argue for D-
mannose to be used as a prophylactic agent in those who suffer from recurrent urinary 
tract infections. Both TMP/SMX and nitrofurantoin are common antibiotics prescribed 
for prevention of recurrent urinary tract infections and the data presented from each study 
demonstrates that D-mannose, when taken regularly, is comparably effective for 
decreasing recurrence or limiting side-effects from the treatment.  
D-mannose is also a cost effective approach to treatment compared to the cost of 
prescription drug use. The current cost of a 4-month supply of D-mannose is $36.42 at a 
drug store in comparison of between $300 to $400 for a 3-month supply of nitrofurantoin 
and $77.70 for TMP-SMX.10-12 This does not include the frequent physician visits needed 
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to obtain prescription refills increasing the annual cost of antibiotic treatment depending 
on insurance coverage.   
According to the reviewed studies4,5 there is very little risk with chronic D-
mannose use, especially when compared to long-term antibiotic use. According to a 
study7 that examined Escherichia coli in urine from over 200 United State laboratories 
from 2000 to 2010, they found TMP/SMX resistance increased from 17.9% to 24.4% and 
nitrofurantoin 0.8% to 1.6% in 10 years. These results do not appear to display a rapid 
growth in resistance; however, these were not the most prescribed antibiotics for urinary 
tract infections. Ciprofloxacin with its broad spectrum coverage, was the most frequently 
prescribed antibiotic for UTIs and consequently had the highest growth in resistance.7 In 
the 10 year study,7 Escherichias coli’s resistance to ciprofloxacin increased from 3% to 
17.1%. This has led to a shifting treatment paradigm from ciprofloxacin to TMP-SMX 
and nitrofurantoin creating a concern for similar resistance of these two medications.  
Despite, the remarkable findings listed in this review, each study has its 
limitations. Kranjcec et al4 excluded diabetic patients from the study, but Porru et al5 did 
not mention the use or exclusion of diabetic participants. The use of D-mannose in 
diabetic mellitus (DM) patients needs to be further evaluated. Considering that the 
supplement is a simple sugar, research needs to be conducted to establish safety of use in 
patients with DM. This factor is essential for providers to be aware of before 
recommending it to their patients.  
The only limitation identified in Kranjcec et al4 was the lack of blinding of both 
the participants and the data collectors as there was no mention of matching the 
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medications including adding the use of a placebo for the no prophylaxis group.  
However, because of the reliability of urine cultures, it is not a serious limitation. 
 Other limitations were identified in the Porru et al5 study during appraisal.  
Because it was a cross-over study, there should have been a washout period. Therefore, 
the participants did not begin the second 24 weeks with the same eligibility criteria of 
acute cystitis. There is an understanding that not all patients would immediately get acute 
cystitis once the treatment was stopped, and it would not be feasible or humane to cause 
this to occur. Additionally, due to this limitation, there should have been separate data 
presented for each 24-week period. This would have revealed whether the greatest 
recurrence of urinary tract infections occurred in the first 24 weeks or the second for each 
group. The only data given identifying a difference in timing is the mean time to 
recurrence.5 
 The final limitation to Porru et al5 is the lack of treatment of the participant’s 
acute cystitis prior to starting the trial. Kranjcec et al4 treated the acute cystitis prior to 
administration of the therapy allowing the study to focus on the prophylactic nature of D-
mannose. Porru et al5 did not separate treatment from prophylaxis; therefore, it cannot 
identify whether D-mannose is better at treating or preventing recurrence of the urinary 
tract infection. The results of the study8 demonstrate a significant enough difference 
making it a less serious limitation.    
 Future studies do need to be completed.  The dosing of D-mannose is not fully 
established.  The Kranjcec et al6 study used 2 g once daily while the Porru et al8  study 
used 3 g in divided doses daily and both demonstrated efficacy in preventing recurrent 
UTIs.  Additionally, it is not clear whether or not D-mannose is safe or effective in 
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patients with diabetes or children. Lastly, longitudinal studies would be beneficial in 
evaluating if there is a similar relapse to recurrency of UTIs as compared to antibiotic 
prophylaxis.  
CONCLUSION 
According to the studies evaluated, D-mannose could be used as a prophylactic 
measure for recurrent urinary tract infections. There is no evidence for the use of D-
mannose as a treatment of urinary tract infections, but once treated, these studies suggest 
a positive response for use to prevent recurrence. However, more studies need to be 
performed to determine the appropriate dose and frequency of the therapy. Long-term 
follow-up would also be beneficial to demonstrate any adverse effects of D-mannose. 
Overall, the current research establishes D-mannose as an efficacious therapy for 
prevention of recurrent urinary tract infections and can be recommended to patients as a 
cost-effective and low-risk option for prevention of uncomplicated recurrent urinary tract 
infections.   
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